Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Binary biotech event live now: early positive “go” in Phase 3 CAPTIVATE interim responder analysis with detailed data discussion/webcast scheduled 2026-03-09–03-10. Stock is up ~40% over 21 days with a 12% intraday jump on the interim news, indicating strong speculative interest and a high-probability volatility window for outsized moves over the next few days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Strong Cash Position • Persistent Cash Burn • Minimal Revenue Base DNTH has exceptional liquidity and low debt, but persistent losses, heavy cash burn, minimal revenue, and an extreme valuation warrant caution.
Price Behavior
Key Price Behavior Insights: • New period low • Accelerating decline • Rebound threshold Support Level: $95.00–$96.80 Resistance Level: $101.00–$102.00 DNTH remains in a short-term downtrend after an 11.6% last-month decline and 8.8% weekly drop to a new low, with rebound potential only if it reclaims $101–$102.
Sentiment & News
Key News Insights: • Institutional accumulation • Workforce expansion • Pipeline funding Dianthus is gaining investor attention through conference activity, major institutional buying, hiring, and a well-funded late-stage autoimmune pipeline.
AI Summary
DNTH's ~$1.2B cash runway materially reduces financing risk through 2030, but its ~$6B valuation is fragile and depends on claseprubart delivering clearly differentiated MMN/CIDP results ahead of pivotal gMG data in 2028—making December 2026 MMN data the key near-term validation catalyst to watch.
Description
Dianthus Therapeutics is a clinical‑stage biotechnology firm developing monoclonal antibody therapies for severe autoimmune and inflammatory diseases. Its lead candidate, DNTH103, is in Phase 1 clinical trials for generalized myasthenia gravis and several immune‑mediated neuropathies. The company was founded in 2015 and is based in New York.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 9 | Mar 16 | DNTH | Dianthus Therapeutics, Inc. | Binary biotech event live now: early positive “go” in Phase 3 CAPTIVATE interim responder analysis with detailed data discussion/webcast scheduled 2026-03-09–03-10. Stock is up ~40% over 21 days with a 12% intraday jump on the interim news, indicating strong speculative interest and a high-probability volatility window for outsized moves over the next few days. | Closed | -1.6% |